AI Engines For more Details: Perplexity Kagi Labs You
Gut Health: L-glutamine is a primary fuel source for the cells lining the intestines (enterocytes) and plays a crucial role in maintaining the integrity and function of the gastrointestinal tract. It helps support the structure and function of the intestinal mucosa, which serves as a barrier against harmful pathogens and toxins. L-glutamine supplementation may help improve gut barrier function, reduce intestinal permeability ("leaky gut"), and alleviate symptoms of gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and leaky gut syndrome.
Immune Function: L-glutamine is important for the proper functioning of the immune system and plays a role in immune cell proliferation, differentiation, and function. It is used as a fuel source by immune cells such as lymphocytes, macrophages, and neutrophils, which are involved in defending the body against infections and diseases. L-glutamine supplementation may help support immune function and enhance the body's ability to mount an immune response to pathogens.
Muscle Recovery: L-glutamine is involved in protein synthesis and muscle tissue repair, making it important for muscle recovery after exercise or injury. It helps reduce muscle breakdown and promote muscle growth and repair. L-glutamine supplementation may help speed up recovery from intense exercise, reduce muscle soreness, and improve overall exercise performance, particularly in athletes and individuals engaged in resistance training.
Wound Healing: L-glutamine plays a critical role in wound healing and tissue repair by providing the necessary building blocks for collagen synthesis and cell proliferation. It helps stimulate fibroblast activity and angiogenesis (formation of new blood vessels), leading to faster healing of wounds, surgical incisions, and injuries. L-glutamine supplementation may help promote wound closure and reduce the risk of wound complications, particularly in individuals with impaired wound healing due to medical conditions such as diabetes or malnutrition.
Stress and Anxiety: L-glutamine may have potential benefits for reducing stress and anxiety levels by supporting neurotransmitter balance in the brain. It serves as a precursor to glutamate and gamma-aminobutyric acid (GABA), two neurotransmitters that play a role in regulating mood, stress responses, and cognitive function. L-glutamine supplementation may help maintain optimal levels of glutamate and GABA, promoting a sense of calmness and well-being.
Metabolic Support: L-glutamine plays a role in various metabolic pathways, including glucose metabolism, ammonia detoxification, and acid-base balance. It serves as a precursor to glucose and helps maintain blood sugar levels during periods of fasting or prolonged exercise. L-glutamine supplementation may be beneficial for individuals with metabolic disorders such as diabetes or liver disease, as well as those undergoing intensive medical treatments such as chemotherapy or surgery.
| Rank | Probiotic | Impact |
|---|---|---|
| order | Micrococcales | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | -0.8 | |
| Acne | 1.3 | 2.1 | -0.62 |
| ADHD | 2.5 | 5 | -1 |
| Age-Related Macular Degeneration and Glaucoma | 0.7 | 0.8 | -0.14 |
| Allergic Rhinitis (Hay Fever) | 0.8 | 1.3 | -0.63 |
| Allergies | 2.8 | 2 | 0.4 |
| Allergy to milk products | 1.9 | 1.9 | 0 |
| Alopecia (Hair Loss) | 2.5 | 2.5 | |
| Alzheimer's disease | 4.4 | 7.7 | -0.75 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 2.8 | 0 |
| Ankylosing spondylitis | 4.2 | 3.2 | 0.31 |
| Anorexia Nervosa | 0.9 | 2.7 | -2 |
| Asthma | 1.8 | 1.7 | 0.06 |
| Atherosclerosis | 1.2 | 1 | 0.2 |
| Atrial fibrillation | 3.5 | 0.7 | 4 |
| Autism | 7.7 | 8.7 | -0.13 |
| Barrett esophagus cancer | 1 | 0.7 | 0.43 |
| benign prostatic hyperplasia | 0.4 | -0.4 | |
| Bipolar Disorder | 2.7 | 4.1 | -0.52 |
| Brain Trauma | 1.3 | 0.4 | 2.25 |
| Breast Cancer | 0.8 | 0.7 | 0.14 |
| Carcinoma | 1.2 | 2 | -0.67 |
| Celiac Disease | 3.4 | 4.4 | -0.29 |
| Cerebral Palsy | 1.1 | 1.5 | -0.36 |
| Chronic Fatigue Syndrome | 1.3 | 4.5 | -2.46 |
| Chronic Kidney Disease | 1.3 | 4.1 | -2.15 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2.1 | -0.4 |
| Chronic Urticaria (Hives) | 2.4 | 0.6 | 3 |
| Coagulation / Micro clot triggering bacteria | 0.2 | 2.4 | -11 |
| Colorectal Cancer | 1.9 | 2.4 | -0.26 |
| Constipation | 2.5 | 0.5 | 4 |
| Coronary artery disease | 1.1 | 2.6 | -1.36 |
| COVID-19 | 6 | 7.2 | -0.2 |
| Crohn's Disease | 7.3 | 5.9 | 0.24 |
| cystic fibrosis | 0.7 | -0.7 | |
| deep vein thrombosis | 2.1 | -2.1 | |
| Depression | 7.1 | 7.3 | -0.03 |
| Dermatomyositis | 0.8 | 1.3 | -0.63 |
| Eczema | 0.7 | 2.1 | -2 |
| Endometriosis | 2.5 | 2.4 | 0.04 |
| Eosinophilic Esophagitis | 0.5 | 2.2 | -3.4 |
| Epilepsy | 4.9 | 2.7 | 0.81 |
| erectile dysfunction | 0.7 | 0.3 | 1.33 |
| Fibromyalgia | 1.9 | 1 | 0.9 |
| Functional constipation / chronic idiopathic constipation | 5.1 | 3.1 | 0.65 |
| gallstone disease (gsd) | 2.7 | 0.4 | 5.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 1.2 | 0.75 |
| Generalized anxiety disorder | 0.8 | 0.2 | 3 |
| Glioblastoma | 1.2 | 1.4 | -0.17 |
| Gout | 0.3 | 2 | -5.67 |
| Graves' disease | 0.8 | 5.4 | -5.75 |
| Halitosis | 1.2 | 0.9 | 0.33 |
| Hashimoto's thyroiditis | 2.5 | 1.6 | 0.56 |
| Heart Failure | 0.2 | 0.2 | |
| Hemorrhoidal disease, Hemorrhoids, Piles | 1.1 | 0.3 | 2.67 |
| Hidradenitis Suppurativa | 1.8 | -1.8 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 0.7 | 0.43 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.8 | -3 |
| hyperglycemia | 0.9 | 0.2 | 3.5 |
| Hyperlipidemia (High Blood Fats) | 1.5 | 0.4 | 2.75 |
| hypersomnia | 0.2 | 0.4 | -1 |
| hypertension (High Blood Pressure | 3.2 | 3.1 | 0.03 |
| Hypothyroidism | 0.5 | 2.2 | -3.4 |
| Hypoxia | 0.6 | 0.6 | 0 |
| IgA nephropathy (IgAN) | 2.2 | 1 | 1.2 |
| Inflammatory Bowel Disease | 3.1 | 3.4 | -0.1 |
| Insomnia | 1.1 | 2.6 | -1.36 |
| Intelligence | 2.6 | 0.7 | 2.71 |
| Intracranial aneurysms | 1.4 | 0.2 | 6 |
| Irritable Bowel Syndrome | 4 | 3.1 | 0.29 |
| Juvenile idiopathic arthritis | 1.2 | -1.2 | |
| Liver Cirrhosis | 4.1 | 3.3 | 0.24 |
| Long COVID | 9.5 | 9.3 | 0.02 |
| Low bone mineral density | 0.9 | 1.4 | -0.56 |
| Lung Cancer | 0.2 | 2 | -9 |
| ME/CFS with IBS | 0.5 | -0.5 | |
| ME/CFS without IBS | 0.4 | 0.7 | -0.75 |
| Menopause | 0.2 | 0.2 | |
| Metabolic Syndrome | 9.2 | 6.7 | 0.37 |
| Mood Disorders | 9.9 | 9.9 | 0 |
| multiple chemical sensitivity [MCS] | 1 | 0.2 | 4 |
| Multiple Sclerosis | 3.6 | 3.3 | 0.09 |
| Multiple system atrophy (MSA) | 0.6 | 1 | -0.67 |
| myasthenia gravis | 0.2 | 0.2 | |
| Neuropathy (all types) | 2.2 | 1.9 | 0.16 |
| neuropsychiatric disorders (PANDAS, PANS) | 2.3 | -2.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 3.3 | 0.24 |
| Obesity | 5.1 | 7.1 | -0.39 |
| obsessive-compulsive disorder | 3.2 | 3 | 0.07 |
| Osteoarthritis | 0.5 | 1.1 | -1.2 |
| Osteoporosis | 1.6 | 2.6 | -0.63 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 3.1 | 5.2 | -0.68 |
| Polycystic ovary syndrome | 1.5 | 1.3 | 0.15 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 1.1 | 0.3 | 2.67 |
| primary biliary cholangitis | 1.8 | 0.3 | 5 |
| Psoriasis | 4.6 | 2.8 | 0.64 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 5.4 | 0.3 |
| Rosacea | 0.2 | 2.4 | -11 |
| Schizophrenia | 5.1 | 5.6 | -0.1 |
| scoliosis | 1.5 | 0.2 | 6.5 |
| sensorineural hearing loss | 0.5 | -0.5 | |
| Sjögren syndrome | 3.2 | 3.3 | -0.03 |
| Sleep Apnea | 2.7 | 1.2 | 1.25 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 1.1 | -2.67 |
| Stress / posttraumatic stress disorder | 1.9 | 2.5 | -0.32 |
| Systemic Lupus Erythematosus | 4.2 | 5.4 | -0.29 |
| Tic Disorder | 1.6 | 1.5 | 0.07 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 4.5 | 3.2 | 0.41 |
| Type 2 Diabetes | 8.1 | 6.1 | 0.33 |
| Ulcerative colitis | 5.8 | 4.7 | 0.23 |
| Unhealthy Ageing | 1.3 | 1.2 | 0.08 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.